MAB Designs

Executive Summary

MAB Designs is a UK-based biotechnology company founded in 2009, specializing in discrete binding antibodies that selectively target specific conformations of antigens. Its proprietary technology aims to differentiate between membrane-bound and shed forms of targets, potentially improving therapeutic efficacy and reducing off-target effects. This approach addresses key limitations in current antibody therapies, particularly in oncology and inflammatory diseases. The company operates in the antibodies and biologics space, with a focus on enhancing drug delivery and diagnostic precision. Despite its innovative platform, MAB Designs remains at an early stage with no disclosed funding rounds, pipeline candidates, or partnerships. The company's private status and limited public information suggest it may still be in the preclinical or research phase. Success will depend on advancing its technology toward proof-of-concept studies, securing funding, and forming strategic collaborations. The biotech landscape for antibody therapeutics is competitive, but MAB Designs' unique conformational selectivity could offer differentiation if validated.

Upcoming Catalysts (preview)

• Q1 2026Series A Funding Round50% success
• Q2 2026Preclinical Proof-of-Concept Data Release40% success
• Q3 2026Strategic Partnership or Licensing Deal30% success